✦ LIBER ✦

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

✍ Scribed by Weijing Sun; James P. Stevenson; Maryann Gallagher; Bruce Giantonio; Kenneth Algazy; Dan Haller; David Vaughn; Barbara J. Raskay; Peter J. O'Dwyer

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 72 KB
Volume: 92
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20010715)92:2<414::aid-cncr1337>3.0.co;2-w

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study to evaluate multiple regim

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors : A potential broadly active regimen for advanced solid tumor malignancies

✍ Sridhar Mani; Nicholas J. Vogelzang; Donna Bertucci; Walter M. Stadler; Richard 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 1 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

A phase I study of ifosfamide with mesna

A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors

✍ Charles B. Pratt; William H. Meyer; Edwin C. Douglass; Laura Bowman; Judith Wili 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 1 views

A Phase I dose escalation trial of conti

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

✍ Todd M. Zimmerman; David L. Grinblatt; Rebecca Malloy; Stephanie F. Williams 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

## BACKGROUND. Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previou